JAMA ophthalmology · 2013
Sensitivity and specificity of the AdenoPlus test for diagnosing adenoviral conjunctivitis.
Сравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sambursky Robert, Trattler William, Tauber Shachar, Starr Christopher, Friedberg Murray, Boland Thomas, McDonald Marguerite, DellaVecchia Michael, Luchs Jodi
Аннотация
OBJECTIVE: To compare the clinical sensitivity and specificity of the AdenoPlus test with those of both viral cell culture (CC) with confirmatory immunofluorescence assay (IFA) and polymerase chain reaction (PCR) at detecting the presence of adenovirus in tear fluid.
METHODS: A prospective, sequential, masked, multicenter clinical trial enrolled 128 patients presenting with a clinical diagnosis of acute viral conjunctivitis from a combination of 8 private ophthalmology practices and academic centers. Patients were tested with AdenoPlus, CC-IFA, and PCR to detect the presence of adenovirus.
MAIN OUTCOME MEASURES: The sensitivity and specificity of AdenoPlus were assessed for identifying cases of adenoviral conjunctivitis.
RESULTS: Of the 128 patients enrolled, 36 patients' results were found to be positive by either CC-IFA or PCR and 29 patients' results were found to be positive by both CC-IFA and PCR. When compared only with CC-IFA, AdenoPlus showed a sensitivity of 90% (28/31) and specificity of 96% (93/97). When compared only with PCR, AdenoPlus showed a sensitivity of 85% (29/34) and specificity of 98% (89/91). When compared with both CC-IFA and PCR, AdenoPlus showed a sensitivity of 93% (27/29) and specificity of 98% (88/90). When compared with PCR, CC-IFA showed a sensitivity of 85% (29/34) and specificity of 99% (90/91).
CONCLUSION: AdenoPlus is sensitive and specific at detecting adenoviral conjunctivitis.
APPLICATION TO CLINICAL PRACTICE: An accurate and rapid in-office test can prevent the misdiagnosis of adenoviral conjunctivitis that leads to the spread of disease, unnecessary antibiotic use, and increased health care costs. Additionally, AdenoPlus may help a clinician make a more informed treatment decision regarding the use of novel therapeutics.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00921895.
METHODS: A prospective, sequential, masked, multicenter clinical trial enrolled 128 patients presenting with a clinical diagnosis of acute viral conjunctivitis from a combination of 8 private ophthalmology practices and academic centers. Patients were tested with AdenoPlus, CC-IFA, and PCR to detect the presence of adenovirus.
MAIN OUTCOME MEASURES: The sensitivity and specificity of AdenoPlus were assessed for identifying cases of adenoviral conjunctivitis.
RESULTS: Of the 128 patients enrolled, 36 patients' results were found to be positive by either CC-IFA or PCR and 29 patients' results were found to be positive by both CC-IFA and PCR. When compared only with CC-IFA, AdenoPlus showed a sensitivity of 90% (28/31) and specificity of 96% (93/97). When compared only with PCR, AdenoPlus showed a sensitivity of 85% (29/34) and specificity of 98% (89/91). When compared with both CC-IFA and PCR, AdenoPlus showed a sensitivity of 93% (27/29) and specificity of 98% (88/90). When compared with PCR, CC-IFA showed a sensitivity of 85% (29/34) and specificity of 99% (90/91).
CONCLUSION: AdenoPlus is sensitive and specific at detecting adenoviral conjunctivitis.
APPLICATION TO CLINICAL PRACTICE: An accurate and rapid in-office test can prevent the misdiagnosis of adenoviral conjunctivitis that leads to the spread of disease, unnecessary antibiotic use, and increased health care costs. Additionally, AdenoPlus may help a clinician make a more informed treatment decision regarding the use of novel therapeutics.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00921895.
Предметные рубрики MeSH
Acute DiseaseAdenovirus Infections, HumanAdenoviruses, HumanAdolescentAdultAgedAged, 80 and overAntigens, ViralChildChild, PreschoolConjunctivitis, ViralDNA, ViralDiagnostic Techniques, OphthalmologicalDouble-Blind MethodFalse Positive ReactionsFemaleFluorescent Antibody TechniqueHumansMaleMiddle AgedPolymerase Chain ReactionPredictive Value of TestsProspective StudiesReproducibility of ResultsSensitivity and SpecificityTearsVirus CultivationYoung Adult